Novartis spinout’s first anti-aging PhIII is a flop, so now they’ll turn to Parkinson’s challenge as shares wilt
Novartis spinout resTORbio is grappling with the collapse of its lead clinical program this morning — an anti-aging R&D failure that will badly damage their rep in the field.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,000+ biopharma pros reading Endpoints daily — and it's free.